Thursday, June 08, 2023 4:27:44 PM
dstock07734,
The mouse model you cited is testing L or an L like product and that needs help in large established tumors.
The Direct mouse model did not get the spacing for Direct figured out exactly but knew that checkpoint response needed to be controlled so they used a checkpoint inhibitor which then helped to establish immune memory.
The real threat NWBO poses is the one that come by establishing the fact that no additional treatments are needed. Whether that comes by more trials (very, very likely) to establish this or not, I am nearly 100% certain that in most cases nothing else will be needed. I know some folks that would benefit from having this option right now and some no longer with us that should have had the opportunity. The science is way ahead of “the process”. Best wishes.
The mouse model you cited is testing L or an L like product and that needs help in large established tumors.
The Direct mouse model did not get the spacing for Direct figured out exactly but knew that checkpoint response needed to be controlled so they used a checkpoint inhibitor which then helped to establish immune memory.
The real threat NWBO poses is the one that come by establishing the fact that no additional treatments are needed. Whether that comes by more trials (very, very likely) to establish this or not, I am nearly 100% certain that in most cases nothing else will be needed. I know some folks that would benefit from having this option right now and some no longer with us that should have had the opportunity. The science is way ahead of “the process”. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
